{
    "organizations": [],
    "uuid": "8cbecd0d4c8de8459cf95c5613b77f87b6cdd5e3",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-shire-says-fda-approves-technology/brief-shire-says-fda-approves-technology-transfer-of-cinryze-manufacturing-process-to-vienna-idUSFWN1PJ0LD",
    "ord_in_thread": 0,
    "title": "BRIEF-Shire says FDA Approves Technology Transfer Of Cinryze Manufacturing Process To Vienna",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Jan 24 (Reuters) - Shire Plc:\n* FDA GRANTS APPROVAL TO SHIRE FOR TECHNOLOGY TRANSFER OF CINRYZE® DRUG PRODUCT MANUFACTURING PROCESS TO VIENNA, AUSTRIA MANUFACTURING SITE\n* ‍SHIRE WILL BEGIN COMMERCIAL MANUFACTURING OF CINRYZE DRUG PRODUCT IN VIENNA IN Q1 OF 2018​\n* ‍CINRYZE WILL ALSO CONTINUE TO BE PRODUCED BY A THIRD-PARTY SUPPLIER, PROVIDING AN ADDITIONAL SUPPLY SOURCE TO MEET PATIENT DEMAND.​ Source text for Eikon: Further company coverage:\n ",
    "published": "2018-01-24T19:03:00.000+02:00",
    "crawled": "2018-01-25T13:05:23.008+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "jan",
        "reuters",
        "shire",
        "plc",
        "fda",
        "grant",
        "approval",
        "shire",
        "technology",
        "transfer",
        "drug",
        "product",
        "manufacturing",
        "process",
        "vienna",
        "austria",
        "manufacturing",
        "site",
        "begin",
        "commercial",
        "manufacturing",
        "cinryze",
        "drug",
        "product",
        "vienna",
        "q1",
        "also",
        "continue",
        "produced",
        "supplier",
        "providing",
        "additional",
        "supply",
        "source",
        "meet",
        "patient",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}